Table 2.
SR-aGVHD characteristics for the group.
| Combination cohort (n = 65) | Retrospective cohort (n = 27) | p value | |
|---|---|---|---|
| Overall grade, n (%) | 0.477 | ||
| III | 21 (32.3) | 11 (40.7) | |
| IV | 44 (67.7) | 16 (59.3) | |
| Skin grade, n (%) | 0.856 | ||
| 0 | 11 (16.9) | 5 (18.5) | |
| I | 4 (6.2) | 3 (11.1) | |
| II | 14 (21.5) | 5 (18.5) | |
| III–IV | 36 (55.4) | 14 (51.8) | |
| Gut grade, n (%) | 0.002 | ||
| 0 | 6 (9.2) | 2 (7.4) | |
| I | 2 (3.1) | 3 (11.1) | |
| II | 1 (1.5) | 6 (22.2) | |
| III–IV | 56 (86.1) | 16 (59.2) | |
| Liver grade, n (%) | 0.281 | ||
| 0 | 23 (35.4) | 15 (55.6) | |
| I | 8 (12.3) | 2 (7.4) | |
| II | 22 (33.8) | 5 (18.5) | |
| III–IV | 12 (18.5) | 5 (18.5) | |
| Combination cohort (n = 65) | Retrospective cohort (n = 27) | p value | |
| Response to treatment/patients evaluable, n (%) | |||
| ORR | 59/65 (90.8) | 12/27 (44.4) | <0.001 |
| CR | 49/65 (75.4) | 8/27 (29.6) | <0.001 |
| CR for skin aGVHD* | 54/54 (100) | 19/19 (100) | 1.0 |
| CR for gut aGVHD)* | 47/59 (79.7) | 8/22 (36.4) | <0.001 |
| CR for liver aGVHD* | 31/42 (73.8%) | 2/10 (20) | 0.003 |
*
Response per organ was assessed among evaluable patients with this organ involvement